Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

BACKGROUND: HVTN 100 evaluated the safety and immunogenicity of an HIV subtype C pox-protein vaccine regimen, investigating a 12-month booster to extend vaccine-induced immune responses. METHODS AND FINDINGS: A phase 1–2 randomized double-blind placebo-controlled trial enrolled 252 participants (210...

Descripción completa

Detalles Bibliográficos
Autores principales: Laher, Fatima, Moodie, Zoe, Cohen, Kristen W., Grunenberg, Nicole, Bekker, Linda-Gail, Allen, Mary, Frahm, Nicole, Yates, Nicole L., Morris, Lynn, Malahleha, Mookho, Mngadi, Kathryn, Daniels, Brodie, Innes, Craig, Saunders, Kevin, Grant, Shannon, Yu, Chenchen, Gilbert, Peter B., Phogat, Sanjay, DiazGranados, Carlos A., Koutsoukos, Marguerite, Van Der Meeren, Olivier, Bentley, Carter, Mkhize, Nonhlanhla N., Pensiero, Michael N., Mehra, Vijay L., Kublin, James G., Corey, Lawrence, Montefiori, David C., Gray, Glenda E., McElrath, M. Juliana, Tomaras, Georgia D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039414/
https://www.ncbi.nlm.nih.gov/pubmed/32092060
http://dx.doi.org/10.1371/journal.pmed.1003038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039414/
https://www.ncbi.nlm.nih.gov/pubmed/32092060
http://dx.doi.org/10.1371/journal.pmed.1003038

Ejemplares similares